TP53 Status and Impact on AML Prognosis Within the ELN 2022 Risk Classification.

Shaun Fleming,Xavier Cheng-Hong Tsai,Rhiannon Morris,Hsin-An Hou, Andrew H. Wei

Blood（2023）

Cited 0|Views6

No score

Abstract

This study reports the following: (1) frequency of TP53 comutation within each component of the European LeukemiaNet 2022 acute myeloid leukemia risk classification, (2) relevance of TP53 mutated variant allelic fraction <10%, (3) prognostic impact of -7,-5/del(5q),-17/abn(17p), complex karyotype/monosomal karyotype, or myelodysplasia-related gene muta-tions with/without mutated TP53.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined